AnaptysBioANAB +5.83%67 Market Cap is $1,840.6 Mil as of Jun. 26, 2026. GuruFocus rates ANAB with a GF Score™ of 67/100 and a GF Value™ of $61.78 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,431 Biotechnology companies, AnaptysBio ranks better than 86.3% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AnaptysBio's share price for the quarter that ended in Mar. 2026 was $36.967862. AnaptysBio's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 29.0 Mil. Therefore, AnaptysBio's market cap for the quarter that ended in Mar. 2026 was $1,073.2 Mil.
AnaptysBio's quarterly market cap
increased
from Sep. 2025 ($562.8 Mil) to Dec. 2025 ($905.4 Mil) and
increased
from Dec. 2025 ($905.4 Mil) to Mar. 2026 ($1,073.2 Mil).
AnaptysBio's annual market cap
declined
from Dec. 2023 ($379.7 Mil) to Dec. 2024 ($268.9 Mil) but then
increased
from Dec. 2024 ($268.9 Mil) to Dec. 2025 ($905.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AnaptysBio's Enterprise Value for Today is $1,564.9 Mil.
AnaptysBio (NAS:ANAB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
AnaptysBio Market Cap Related Terms
AnaptysBio Market Cap Historical Data
* Premium members only.
The historical data trend for AnaptysBio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AnaptysBio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnaptysBio Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnaptysBio's Market Cap distribution charts can be found below:
* The bar in red indicates where AnaptysBio's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
AnaptysBio's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnaptysBio (ANAB) has a Market Cap of $1,840.6 Mil as of Jun. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on AnaptysBio and its competitors. According to the industry distribution chart, AnaptysBio ranks #196 out of 1431 companies in the Biotechnology industry, placing it in the top 13.7%.
Is AnaptysBio's Market Cap too high?
AnaptysBio's current Market Cap is $1,840.6 Mil. The Biotechnology industry median Market Cap is 113.83. AnaptysBio's value of $1,840.6 Mil is 1517% above this industry median. Based on the distribution chart, AnaptysBio ranks #196 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AnaptysBio has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AnaptysBio's Market Cap compare to VIR and GHRS?
According to the Biotechnology industry distribution chart, AnaptysBio ranks #196 out of 1431 companies for Market Cap. This places AnaptysBio in the top 14% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.83. AnaptysBio's value of $1,840.6 Mil is 1517% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.83, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AnaptysBio's current Market Cap of $1,840.6 Mil is 1517% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on AnaptysBio and its competitors. For the Biotechnology industry, the median Market Cap is 113.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AnaptysBio's current Market Cap is $1,840.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnaptysBio stock overvalued right now?
Based on GuruFocus' analysis, AnaptysBio (ANAB) is currently considered Fairly Valued. The stock's GF Value™ is $61.78, compared to a current price of $63.25 — trading 2.4% above its estimated fair value. The current Market Cap is $1,840.6 Mil and 1517% above the Biotechnology industry median of 113.83. AnaptysBio's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For AnaptysBio (ANAB), the current Market Cap is $1,840.6 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnaptysBio (ANAB) Overvalued in 2026?
Based on GuruFocus' analysis, AnaptysBio stock appears to be overvalued.
The current stock price of $63.25 is trading 2.4% above its estimated GF Value™ of $61.78.
GuruFocus considers AnaptysBio to be Fairly Valued.
Key valuation signals for ANAB:
Market Cap: $1,840.6 Mil
GF Value™: $61.78 vs. price of $63.25 (2.4% above fair value)
Industry Position: 1517% above the Biotechnology median (#196 of 1431)
No single metric tells the full story. See the ANAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
67GF Score
Get the complete analysis for ANAB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANAB has been successfully added to your 
